New drug takes aim at Hard-to-Treat blood cancers

NCT ID NCT04830137

Recruiting now Disease control Sponsor: Nurix Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new oral drug called NX-2127 in adults with advanced B-cell cancers (like certain leukemias and lymphomas) that have not responded to standard treatments. The drug works by breaking down a protein that helps cancer cells grow. The main goals are to check safety, find the right dose, and see if it shrinks tumors. About 248 people will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NX-2127 (a drug that breaks down a protein called BTK to help fight cancer)
What this could lead to: If it works, this could offer a new treatment option for people with advanced B-cell cancers that have stopped responding to other therapies.
What could go wrong: This is a very early Phase 1 trial, so the drug may not work or could have serious side effects. It is only for patients who have already tried other treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia diffuse large B-cell lymphoma follicular lymphoma lymphoma Lymphoma, B-Cell, Marginal Zone mantle cell lymphoma marginal zone lymphoma primary central nervous system lymphoma Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL) FOLLICULAR LYMPHOMA (FL) MANTLE CELL LYMPHOMA (MCL) MARGINAL ZONE LYMPHOMA (MZL) PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) SMALL LYMPHOCYTIC LYMPHOMA (SLL) WALDENSTROM MACROGLOBULINEMIA (WM)

Contacts and locations

Locations

Baylor University Medical Center
COMPLETED

Dallas, Texas, 75246, United States
City of Hope
RECRUITING

Duarte, California, 91010, United States
Huntsman Cancer Institute, University of Utah
RECRUITING

Salt Lake City, Utah, 84112, United States
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Memorial Sloan Kettering Cancer Center
COMPLETED

New York, New York, 10065, United States
Mount Sinai Comprehensive Cancer Center
COMPLETED

Miami Beach, Florida, 33140, United States
National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20814, United States
OSU Wexner Medical Center
COMPLETED

Columbus, Ohio, 43210, United States
Sarah Cannon Research Institute at Colorado Blood Cancer Institute
RECRUITING

Denver, Colorado, 80218, United States
Sarah Cannon Research Institute at Florida Cancer Specialists
COMPLETED

Sarasota, Florida, 34203, United States
Swedish Cancer Institute
COMPLETED

Seattle, Washington, 98104, United States
Tennessee Oncology
RECRUITING

Nashville, Tennessee, 37203, United States
The University of Chicago Medical Center
RECRUITING

Chicago, Illinois, 60637, United States
University of California Irvine
COMPLETED

Orange, California, 92868, United States
University of California San Francisco Medical Center
COMPLETED

San Francisco, California, 94143, United States
University of Cincinnati Medical Center
COMPLETED

Cincinnati, Ohio, 45267, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.